Bone sialoprotein: a multifunctional regulator of bone remodelling and tumour progression

Abstract

Bone sialoprotein (BSP) is a major non-collagenous protein of the bone extracellular matrix and an important regulator of bone formation and resorption. BSP is produced by bone cells and chondrocytes and present in the bone matrix, cells, dentin and cartilage. However, its aberrant expression in primary tumour tissues and the sera of cancer patients with metastases implicates BSP in tumour biology and progression. The Arg-Gly-Asp (RGD) motif of BSP may be crucial not only for the attachment of metastasising cells to the bone surface but also for tumour growth, survival and activity. This review examines the structure and functions of BSP, including its roles in angiogenesis, bone formation, osteoclast differentiation and activity and cancer cell proliferation, survival, complement evasion, adhesion, migration and invasion. Growing evidence highlights BSP as a key mediator of tumour pathophysiology, skeletal metastasis development and associated bone remodelling. These processes are driven through RGD-integrin binding, the integrin/BSP/matrix metalloproteinase axis, integrin-independent signalling pathways, epithelial-to-mesenchymal transition and potentially post-translational modifications. A deeper understanding of BSP’s role in tumour progression may reinforce its potential as a prognostic and diagnostic tumour biomarker and aid the development of anti-BSP antibodies or targeted inhibitors for skeletal metastases and bone diseases.

References

[1] Staines KA, MacRae VE, Farquharson C. The importance of the SIBLING family of proteins on skeletal mineralisation and bone remodelling. J. Endocrinol., 2012, 214: 241-255

[2] Fisher LW, Fedarko NS. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res., 2003, 44: 33-40

[3] Young MF, Ibaraki K, Kerr JM, Lyu MS, Kozak CA. Murine bone sialoprotein (BSP): cDNA cloning, mRNA expression, and genetic mapping. Mamm. Genome, 1994, 5: 108-111

[4] Bianco P, Fisher LW, Young MF, Termine JD, Robey PG. Expression of bone sialoprotein (BSP) in developing human tissues. Calcif. Tissue Int., 1991, 49: 421-426

[5] Butler WT, Ritchie H. The nature and functional significance of dentin extracellular matrix proteins. Int. J. Dev. Biol., 1995, 39: 169-179

[6] Qin C, Baba O, Butler WT. Post-translational modifications of sibling proteins and their roles in osteogenesis and dentinogenesis. Crit. Rev. Oral. Biol. Med., 2004, 15: 126-136

[7] National Library of Medicine (US), N. C. f. B. I. IBSP integrin binding sialoprotein [Homo sapiens (human)], https://www.ncbi.nlm.nih.gov/gene/3381 (2004).

[8] Ogata Y. Bone sialoprotein and its transcriptional regulatory mechanism. J. Periodontal Res., 2008, 43: 127-135

[9] Bouleftour W, et al.. The role of the SIBLING, bone sialoprotein in skeletal biology—contribution of mouse experimental genetics. Matrix Biol., 2016, 52-54: 60-77

[10] Kim RH, Shapiro HS, Li JJ, Wrana JL, Sodek J. Characterization of the human bone sialoprotein (BSP) gene and its promoter sequence. Matrix Biol., 1994, 14: 31-40

[11] Li JJ, Kim RH, Sodek J. An inverted TATA box directs downstream transcription of the bone sialoprotein gene. Biochem. J., 1995, 310: 33-40

[12] Araki S, et al.. Parathyroid hormone regulation of the human bone sialoprotein gene transcription is mediated through two cAMP response elements. J. Cell. Biochem., 2009, 106: 618-625

[13] Huang WC, et al.. Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res., 2005, 65: 2303-2313

[14] Matsumura H, Nakayama Y, Takai H, Ogata Y. Effects of interleukin-11 on the expression of human bone sialoprotein gene. J. Bone Miner. Metab., 2015, 33: 142-153

[15] Barnes GL, et al.. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res., 2003, 63: 2631-2637

[16] Detry C, Lamour V, Castronovo V, Bellahcene A. CREB-1 and AP-1 transcription factors JunD and Fra-2 regulate bone sialoprotein gene expression in human breast cancer cells. Bone, 2008, 42: 422-431

[17] Mezawa M, et al.. Regulation of human bone sialoprotein gene transcription by platelet-derived growth factor-BB. Gene, 2009, 435: 80-87

[18] Ding W, Lv D, Wang M, Pei D. IBSP promotes breast cancer bone metastasis and proliferation via BMP-SMAD signaling pathway. Cancer Rep., 2024, 7: e2153

[19] Li Z, et al.. cAMP and fibroblast growth factor 2 regulate bone sialoprotein gene expression in human prostate cancer cells. Gene, 2011, 471: 1-12

[20] Zhou L, Ogata Y. Transcriptional regulation of the human bone sialoprotein gene by fibroblast growth factor 2. J. Oral. Sci., 2013, 55: 63-70

[21] UniProt. the universal protein knowledgebase in 2023. Nucleic Acids Res., 2023, 51: D523-D531

[22] Zaia J, Boynton R, Heinegard D, Barry F. Posttranslational modifications to human bone sialoprotein determined by mass spectrometry. Biochemistry, 2001, 40: 12983-12991

[23] Fisher LW, Hawkins GR, Tuross N, Termine JD. Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. J. Biol. Chem., 1987, 262: 9702-9708

[24] Wuttke M, et al.. Structural characterization of human recombinant and bone-derived bone sialoprotein: functional implications for cell attachment and hydroxyapatite binding. J. Biol. Chem., 2001, 276: 36839-36848

[25] George A, Veis A. Phosphorylated proteins and control over apatite nucleation, crystal growth, and inhibition. Chem. Rev., 2008, 108: 4670-4693

[26] Yang Y, Cui Q, Sahai N. How does bone sialoprotein promote the nucleation of hydroxyapatite? A molecular dynamics study using model peptides of different conformations. Langmuir, 2010, 26: 9848-9859

[27] Stubbs JT, et al.. Characterization of native and recombinant bone sialoprotein: delineation of the mineral-binding and cell adhesion domains and structural analysis of the RGD domain. J. Bone Miner. Res., 1997, 12: 1210-1222

[28] Rezania A, Healy KE. Biomimetic peptide surfaces that regulate adhesion, spreading, cytoskeletal organization, and mineralization of the matrix deposited by osteoblast-like cells. Biotechnol. Prog., 1999, 15: 19-32

[29] Choi YJ, Lee JY, Chung CP, Park YJ. Enhanced osteogenesis by collagen-binding peptide from bone sialoprotein in vitro and in vivo. J. Biomed. Mater. Res. A, 2013, 101: 547-554

[30] Tye CE, Hunter GK, Goldberg HA. Identification of the type I collagen-binding domain of bone sialoprotein and characterization of the mechanism of interaction. J. Biol. Chem., 2005, 280: 13487-13492

[31] Gordon JA, et al.. Bone sialoprotein expression enhances osteoblast differentiation and matrix mineralization in vitro. Bone, 2007, 41: 462-473

[32] Raynal C, Delmas PD, Chenu C. Bone sialoprotein stimulates in vitro bone resorption. Endocrinology, 1996, 137: 2347-2354

[33] Goldberg HA, Warner KJ, Li MC, Hunter GK. Binding of bone sialoprotein, osteopontin and synthetic polypeptides to hydroxyapatite. Connect Tissue Res., 2001, 42: 25-37

[34] Hunter GK, Goldberg HA. Modulation of crystal formation by bone phosphoproteins: role of glutamic acid-rich sequences in the nucleation of hydroxyapatite by bone sialoprotein. Biochem. J., 1994, 302: 175-179

[35] Tye CE, et al.. Delineation of the hydroxyapatite-nucleating domains of bone sialoprotein. J. Biol. Chem., 2003, 278: 7949-7955

[36] Wazen RM, et al.. In vivo functional analysis of polyglutamic acid domains in recombinant bone sialoprotein. J. Histochem. Cytochem., 2007, 55: 35-42

[37] Goldberg HA, Warner KJ, Stillman MJ, Hunter GK. Determination of the hydroxyapatite-nucleating region of bone sialoprotein. Connect. Tissue Res., 1996, 35: 385-392

[38] Gordon JA, Sodek J, Hunter GK, Goldberg HA. Bone sialoprotein stimulates focal adhesion-related signaling pathways: role in migration and survival of breast and prostate cancer cells. J. Cell Biochem., 2009, 107: 1118-1128

[39] van der Pluijm G, et al.. Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. Cancer Res., 1996, 56: 1948-1955

[40] Fisher LW, McBride OW, Termine JD, Young MF. Human bone sialoprotein. Deduced protein sequence and chromosomal localization. J. Biol. Chem., 1990, 265: 2347-2351

[41] Fujisawa R, Nodasaka Y, Kuboki Y. Further characterization of interaction between bone sialoprotein (BSP) and collagen. Calcif. Tissue Int., 1995, 56: 140-144

[42] Larsson E, Luning B, Heinegard D. Synthesis and function of an O-phosphorylated peptide corresponding to the cell adhesion sequence of bone sialoprotein (BSP). Acta Chem. Scand., 1993, 47: 565-569

[43] Curtin P, et al.. Modulation of bone resorption by phosphorylation state of bone sialoprotein. Biochemistry, 2009, 48: 6876-6886

[44] Baht GS, et al.. Phosphorylation of Ser136 is critical for potent bone sialoprotein-mediated nucleation of hydroxyapatite crystals. Biochem. J., 2010, 428: 385-395

[45] Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem. Biophys. Res. Commun., 2001, 280: 460-465

[46] Domon S, Shimokawa H, Yamaguchi S, Soma K. Temporal and spatial mRNA expression of bone sialoprotein and type I collagen during rodent tooth movement. Eur. J. Orthod., 2001, 23: 339-348

[47] Kreke MR, Huckle WR, Goldstein AS. Fluid flow stimulates expression of osteopontin and bone sialoprotein by bone marrow stromal cells in a temporally dependent manner. Bone, 2005, 36: 1047-1055

[48] Chenu C, Delmas PD. Platelets contribute to circulating levels of bone sialoprotein in human. J. Bone Miner. Res., 1992, 7: 47-54

[49] Fisher LW, Jain A, Tayback M, Fedarko NS. Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clin. Cancer Res., 2004, 10: 8501-8511

[50] Ibrahim T, et al.. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin. Exp. Metastas., 2000, 18: 253-260

[51] Yang R, Gerstenfeld LC. Signal transduction pathways mediating parathyroid hormone stimulation of bone sialoprotein gene expression in osteoblasts. J. Biol. Chem., 1996, 271: 29839-29846

[52] Ouyang H, Franceschi RT, McCauley LK, Wang D, Somerman MJ. Parathyroid hormone-related protein down-regulates bone sialoprotein gene expression in cementoblasts: role of the protein kinase A pathway. Endocrinology, 2000, 141: 4671-4680

[53] Takai H, et al.. Unliganded estrogen receptor α stimulates bone sialoprotein gene expression. Gene, 2014, 539: 50-57

[54] Chen J, Thomas HF, Sodek J. Regulation of bone sialoprotein and osteopontin mRNA expression by dexamethasone and 1,25-dihydroxyvitamin D3 in rat bone organ cultures. Connect. Tissue Res., 1996, 34: 41-51

[55] Liu BH, et al.. Interleukin-8 promotes prostate cancer bone metastasis through upregulation of bone sialoprotein. Oncol. Lett., 2019, 17: 4607-4613

[56] Wang S, et al.. Transcriptional regulation of bone sialoprotein gene by interleukin-11. Gene, 2011, 476: 46-55

[57] Shimizu E, et al.. Fibroblast growth factor 2 and cyclic AMP synergistically regulate bone sialoprotein gene expression. Bone, 2006, 39: 42-52

[58] Choe J, et al.. Insulin-like growth factor-II regulates bone sialoprotein gene transcription. Odontology, 2016, 104: 271-281

[59] Samoto H, et al.. TNF-alpha suppresses bone sialoprotein (BSP) expression in ROS17/2.8 cells. J. Cell Biochem., 2002, 87: 313-323

[60] Wang S, Sasaki Y, Ogata Y. Calcium hydroxide regulates bone sialoprotein gene transcription in human osteoblast-like Saos2 cells. J. Oral. Sci., 2011, 53: 77-86

[61] Wang S, et al.. Calcium hydroxide regulates transcription of the bone sialoprotein gene via a calcium-sensing receptor in osteoblast-like ROS 17/2.8 cells. Eur. J. Oral. Sci., 2018, 126: 13-23

[62] Keller, F., Bruch, R., Clauder, F., Hafner, M. & Rudolf, R. Extracellular matrix components regulate bone sialoprotein expression in MDA-MB-231 breast cancer cells. Cells10, 1304 (2021).

[63] Mosig RA, Martignetti JA. Loss of MMP-2 in murine osteoblasts upregulates osteopontin and bone sialoprotein expression in a circuit regulating bone homeostasis. Dis. Model. Mech., 2013, 6: 397-403

[64] Cogan G, et al.. Analysis of human bone sialoprotein in normal and pathological tissues using a monoclonal antibody (BSP 1.2 mab). Connect. Tissue Res., 2004, 45: 60-71

[65] Grzesik WJ, Robey PG. Bone matrix RGD glycoproteins: immunolocalization and interaction with human primary osteoblastic bone cells in vitro. J. Bone Miner. Res., 1994, 9: 487-496

[66] Fisher LW, Whitson SW, Avioli LV, Termine JD. Matrix sialoprotein of developing bone. J. Biol. Chem., 1983, 258: 12723-12727

[67] Fujisawa R, Butler WT, Brunn JC, Zhou HY, Kuboki Y. Differences in composition of cell-attachment sialoproteins between dentin and bone. J. Dent. Res., 1993, 72: 1222-1226

[68] Righi L, et al.. Prognostic role of bone sialoprotein in clear cell renal carcinoma. Anticancer Res., 2013, 33: 2679-2687

[69] Kayed H, et al.. Effects of bone sialoprotein on pancreatic cancer cell growth, invasion and metastasis. Cancer Lett., 2007, 245: 171-183

[70] Bellahcène A, Kroll M, Liebens F, Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J. Bone Miner. Res., 1996, 11: 665-670

[71] Waltregny D, et al.. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J. Natl. Cancer Inst., 1998, 90: 1000-1008

[72] Bellahcene A, et al.. Bone sialoprotein mRNA and protein expression in human multiple myeloma cell lines and patients. Br. J. Haematol., 2000, 111: 1118-1121

[73] Wang L, et al.. Bone sialoprotein-alphavbeta3 integrin axis promotes breast cancer metastasis to the bone. Cancer Sci., 2019, 110: 3157-3172

[74] Papotti M, et al.. Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study. J. Clin. Oncol., 2006, 24: 4818-4824

[75] Ebert W, Muley T, Herb KP, Schmidt-Gayk H. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res., 2004, 24: 3193-3201

[76] Harvey HA. Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma. Cancer, 1997, 80: 1646-1651

[77] Roudier MP, et al.. Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat. Res., 2004, 118: 311-339

[78] Bellahcene A, Merville MP, Castronovo V. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res., 1994, 54: 2823-2826

[79] Bellahcene A, et al.. Expression of bone sialoprotein in human lung cancer. Calcif. Tissue Int., 1997, 61: 183-188

[80] Paget S. The distribution of secondary growths in cancer of the breast. Lancet, 1889, 133: 571-573

[81] Li ZN, et al.. Improved specificity and reduced subtype cross-reactivity for antibody detection by ELISA using globular head domain recombinant hemagglutinin. J. Virol. Methods, 2014, 209: 121-125

[82] Hu S, Huang Z, Wang C, Peng J, Lai WH. Using hapten cross-reactivity to screen heterologous competitive antigens for improving the sensitivity of ELISA. Food Chem., 2020, 303: 125379

[83] Gan SD, Patel KR. Enzyme immunoassay and enzyme-linked immunosorbent assay. J. Invest. Dermatol., 2013, 133 e12

[84] Woitge HW, et al.. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br. J. Cancer, 2001, 84: 344-351

[85] He JJ, Zhi K, Liu GF. Predictive value of serum bone sialoprotein in patients with bone metastasis of non-small cell lung cancer. Onkologie, 2011, 34: 584-588

[86] Jain A, et al.. Small integrin-binding proteins as serum markers for prostate cancer detection. Clin. Cancer Res., 2009, 15: 5199-5207

[87] Wei, R. J. et al. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases. Genet. Mol. Res.15, https://doi.org/10.4238/gmr.15027707 (2016).

[88] Loosen SH, et al.. Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma. Sci. Rep., 2019, 9 1489

[89] Bellahcene A, Menard S, Bufalino R, Moreau L, Castronovo V. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int. J. Cancer, 1996, 69: 350-353

[90] Ma Y, et al.. High expression of integrin-binding sialoprotein (IBSP) is associated with poor prognosis of osteosarcoma. Aging, 2023, 16: 28-42

[91] Xu T, et al.. High bone sialoprotein (BSP) expression correlates with increased tumor grade and predicts a poorer prognosis of high-grade glioma patients. PLoS One, 2012, 7: e48415

[92] Chen WC, et al.. Bone sialoprotein promotes lung cancer osteolytic bone metastasis via MMP14-dependent mechanisms. Biochem. Pharm., 2023, 211: 115540

[93] DiPietro LA. Angiogenesis and wound repair: when enough is enough. J. Leukoc. Biol., 2016, 100: 979-984

[94] Huang C, et al.. Spatiotemporal analyses of osteogenesis and angiogenesis via intravital imaging in cranial bone defect repair. J. Bone Miner. Res., 2015, 30: 1217-1230

[95] Bielenberg DR, Zetter BR. The contribution of angiogenesis to the process of metastasis. Cancer J., 2015, 21: 267-273

[96] Jain A, Fisher LW, Fedarko NS. Bone sialoprotein binding to matrix metalloproteinase-2 alters enzyme inhibition kinetics. Biochemistry, 2008, 47: 5986-5995

[97] Kriegel, A. et al. Bone sialoprotein immobilized in collagen type I enhances angiogenesis in vitro and in ovo. Polymers15, 1007 (2023).

[98] Bellahcene A, et al.. Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis. Circ. Res., 2000, 86: 885-891

[99] Valverde P, et al.. Overexpression of bone sialoprotein leads to an uncoupling of bone formation and bone resorption in mice. J. Bone Miner. Res., 2008, 23: 1775-1788

[100] Malaval L, et al.. Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J. Exp. Med., 2008, 205: 1145-1153

[101] Hunter GK, Hauschka PV, Poole RA, Rosenberg LC, Goldberg HA. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem. J., 1996, 317: 59-64

[102] Zhu XL, Ganss B, Goldberg HA, Sodek J. Synthesis and processing of bone sialoproteins during de novo bone formation in vitro. Biochem. Cell Biol., 2001, 79: 737-746

[103] Valverde P, Tu Q, Chen J. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. J. Bone Miner. Res., 2005, 20: 1669-1679

[104] Boudiffa M, et al.. Bone sialoprotein deficiency impairs osteoclastogenesis and mineral resorption in vitro. J. Bone Miner. Res., 2010, 25: 2669-2679

[105] Lossdörfer S, Götz W. & Jäger, A. PTH (1-34)-induced changes in RANKL and OPG expression by human PDL cells modify osteoclast biology in a co-culture model with RAW 264.7 cells. Clin. Oral. Investig., 2011, 15: 941-952

[106] Huang XL, et al.. Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-kappaB and JNK signalling pathways. Int. J. Mol. Med., 2019, 44: 582-592

[107] Moon JB, et al.. Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade. J. Immunol., 2012, 188: 163-169

[108] Paniccia R, et al.. Calcitonin down-regulates immediate cell signals induced in human osteoclast-like cells by the bone sialoprotein-IIA fragment through a postintegrin receptor mechanism. Endocrinology, 1995, 136: 1177-1186

[109] Song C, et al.. Evaluation of efficacy on RANKL induced osteoclast from RAW264.7 cells. J. Cell Physiol., 2019, 234: 11969-11975

[110] Cheng Y, et al.. Evaluation of culture conditions for osteoclastogenesis in RAW264.7 cells. PLoS One, 2022, 17: e0277871

[111] Li ZH, et al.. High-dose PMA with RANKL and MCSF induces THP‑1 cell differentiation into human functional osteoclasts in vitro. Mol. Med. Rep., 2017, 16: 8380-8384

[112] Henriksen K, Karsdal MA, Taylor A, Tosh D, Coxon FP. Generation of human osteoclasts from peripheral blood. Methods Mol. Biol., 2012, 816: 159-175

[113] Bernhardt, A., Schamel, M., Gbureck, U. & Gelinsky, M. Osteoclastic differentiation and resorption is modulated by bioactive metal ions Co, Cu and Cr incorporated into calcium phosphate bone cements. PLoS One12, e0182109 (2017).

[114] Ishijima M, et al.. Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J. Exp. Med., 2001, 193: 399-404

[115] Ross FP, et al.. Interactions between the bone-matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha-v-beta-3 potentiate bone-resorption. J. Biol. Chem., 1993, 268: 9901-9907

[116] Addison WN, Azari F, Sorensen ES, Kaartinen MT, McKee MD. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J. Biol. Chem., 2007, 282: 15872-15883

[117] Monfoulet L, et al.. Bone sialoprotein, but not osteopontin, deficiency impairs the mineralization of regenerating bone during cortical defect healing. Bone, 2010, 46: 447-452

[118] Feitelson MA, et al.. Sustained proliferation in cancer: mechanisms and novel therapeutic targets. Semin Cancer Biol., 2015, 35: S25-S54

[119] Adan A, Kiraz Y, Baran Y. Cell proliferation and cytotoxicity assays. Curr. Pharm. Biotechnol., 2016, 17: 1213-1221

[120] Dojindo. Measuring Cell Viability/Cytotoxicity, https://www.dojindo.com/EUROPE/products/CK04/img/Cell%20Proliferation%20Cytotoxicity%20Assay%20Protocol.pdf#page=1.16.

[121] Borowicz, S. et al. The soft agar colony formation assay. J. Vis. Exp. (2014).

[122] Sung V, Stubbs JT3rd, Fisher L, Aaron AD, Thompson EW. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J. Cell Physiol., 1998, 176: 482-494

[123] Reufsteck C, et al.. Silencing of skeletal metastasis-associated genes impairs migration of breast cancer cells and reduces osteolytic bone lesions. Clin. Exp. Metastasis, 2012, 29: 441-456

[124] Kovacheva M, Zepp M, Berger SM, Berger MR. Sustained conditional knockdown reveals intracellular bone sialoprotein as essential for breast cancer skeletal metastasis. Oncotarget, 2014, 5: 5510-5522

[125] Sharp JA, Waltham M, Williams ED, Henderson MA, Thompson EW. Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion in vitro and growth of primary and secondary tumors in nude mice. Clin. Exp. Metastasis, 2004, 21: 19-29

[126] Yang J, et al.. Interaction of the tumor suppressor SMAD4 and WNT signaling in progression to oral squamous cell carcinoma. J. Pathol., 2024, 264: 4-16

[127] Xu K, et al.. PARP1 bound to XRCC2 promotes tumor progression in colorectal cancer. Discov. Oncol., 2024, 15: 238

[128] Guadamillas MC, Cerezo A, Del Pozo MA. Overcoming anoikis–pathways to anchorage-independent growth in cancer. J. cell Sci., 2011, 124: 3189-3197

[129] Neophytou, C. M., Panagi, M., Stylianopoulos, T. & Papageorgis, P. The role of tumor microenvironment in cancer metastasis: molecular mechanisms and therapeutic opportunities. Cancers13, 2053 (2021).

[130] Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32 825 patients. Breast, 2008, 17: 323-334

[131] Rustamov V, Keller F, Klicks J, Hafner M, Rudolf R. Bone sialoprotein shows enhanced expression in early, high-proliferation stages of three-dimensional spheroid cell cultures of breast cancer cell line MDA-MB-231. Front. Oncol., 2019, 9: 36

[132] Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother. Pharm., 2005, 56: 46-54

[133] Longo PG, et al.. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood, 2008, 111: 846-855

[134] Steffen JD, et al.. Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer. Cancer Res., 2014, 74: 31-37

[135] Thuong LHH, et al.. Bone sialoprotein facilitates anoikis resistance in lung cancer by inhibiting miR-150-5p expression. J. Cell. Mol. Med., 2024, 28 e70155

[136] Wu Z, et al.. Higher expression of miR-150-5p promotes tumorigenesis by suppressing LKB1 in non-small cell lung cancer. Pathol. Res. Pract., 2020, 216 153145

[137] Ameri A, et al.. Diverse activity of miR-150 in Tumor development: shedding light on the potential mechanisms. Cancer Cell Int., 2023, 23 261

[138] Ferreira VP, Herbert AP, Hocking HG, Barlow PN, Pangburn MK. Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces. J. Immunol., 2006, 177: 6308-6316

[139] Jozsi M, Oppermann M, Lambris JD, Zipfel PF. The C-terminus of complement factor H is essential for host cell protection. Mol. Immunol., 2007, 44: 2697-2706

[140] Kishore U, Sim RB. Factor H as a regulator of the classical pathway activation. Immunobiology, 2012, 217: 162-168

[141] Fedarko NS, Fohr B, Robey PG, Young MF, Fisher LW. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J. Biol. Chem., 2000, 275: 16666-16672

[142] Kim EK, et al.. Tumor-derived osteopontin suppresses antitumor immunity by promoting extramedullary myelopoiesis. Cancer Res., 2014, 74: 6705-6716

[143] Klement JD, et al.. An osteopontin/CD44 immune checkpoint controls CD8 T cell activation and tumor immune evasion. J. Clin. Invest., 2018, 128: 5549-5560

[144] Cai S, et al.. Recent advance in surface modification for regulating cell adhesion and behaviors. Nanotechnol. Rev., 2020, 9: 971-989

[145] Taylor L, Wankell M, Saxena P, McFarlane C, Hebbard L. Cell adhesion an important determinant of myogenesis and satellite cell activity. Biochim. Biophys. Acta Mol. Cell Res., 2022, 1869: 119170

[146] Krakhmal NV, Zavyalova M, Denisov E, Vtorushin S, Perelmuter V. Cancer invasion: patterns and mechanisms. Acta Nat., 2015, 7: 17-28

[147] Byzova TV, Kim W, Midura RJ, Plow EF. Activation of integrin alpha(V)beta(3) regulates cell adhesion and migration to bone sialoprotein. Exp. Cell Res., 2000, 254: 299-308

[148] Kottmann V, et al.. Bone sialoprotein stimulates cancer cell adhesion through the RGD motif and the alphavbeta3 and alphavbeta5 integrin receptors. Oncol. Lett., 2024, 28: 542

[149] Bernards MT, Qin C, Ratner BD, Jiang S. Adhesion of MC3T3-E1 cells to bone sialoprotein and bone osteopontin specifically bound to collagen I. J. Biomed. Mater. Res. A, 2008, 86: 779-787

[150] Wells A, Huttenlocher A, Lauffenburger DA. Calpain proteases in cell adhesion and motility. Int. Rev. Cytol., 2005, 245: 1-16

[151] Christensen B, et al.. Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J. Biol. Chem., 2007, 282: 19463-19472

[152] Seger D, Gechtman Z, Shaltiel S. Phosphorylation of vitronectin by casein kinase II: identification of the sites and their promotion of cell adhesion and spreading. J. Biol. Chem., 1998, 273: 24805-24813

[153] Kanan Y, Siefert JC, Kinter M, Al-Ubaidi MR. Complement factor H, vitronectin, and opticin are tyrosine-sulfated proteins of the retinal pigment epithelium. PLoS One, 2014, 9: e105409

[154] Ewald AJ, Brenot A, Duong M, Chan BS, Werb Z. Collective epithelial migration and cell rearrangements drive mammary branching morphogenesis. Dev. Cell, 2008, 14: 570-581

[155] Poujade M, et al.. Collective migration of an epithelial monolayer in response to a model wound. Proc. Natl. Acad. Sci., 2007, 104: 15988-15993

[156] Hegerfeldt Y, Tusch M, Brocker EB, Friedl P. Collective cell movement in primary melanoma explants: plasticity of cell-cell interaction, beta1-integrin function, and migration strategies. Cancer Res., 2002, 62: 2125-2130

[157] Karadag A, Ogbureke KU, Fedarko NS, Fisher LW. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J. Natl. Cancer Inst., 2004, 96: 956-965

[158] Ghochani Y, et al.. A molecular interactome of the glioblastoma perivascular niche reveals integrin binding sialoprotein as a mediator of tumor cell migration. Cell Rep., 2022, 41: 111511

[159] Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol. Int., 2002, 52: 255-264

[160] Anunobi CC, Koli K, Saxena G, Banjo AA, Ogbureke KU. Expression of the SIBLINGs and their MMP partners in human benign and malignant prostate neoplasms. Oncotarget, 2016, 7: 48038-48049

[161] Fedarko NS, Jain A, Karadag A, Fisher LW. Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J., 2004, 18: 734-736

[162] Chan KT, Bennin DA, Huttenlocher A. Regulation of adhesion dynamics by calpain-mediated proteolysis of focal adhesion kinase (FAK). J. Biol. Chem., 2010, 285: 11418-11426

[163] Al-Shami R, et al.. Phosphorylated osteopontin promotes migration of human choriocarcinoma cells via a p70 S6 kinase-dependent pathway. J. Cell. Biochem., 2005, 94: 1218-1233

[164] Adwan H, Bäuerle TJ, Berger MR. Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther., 2004, 11: 109-120

[165] Hussain M, et al.. Differential effect on bone lesions of targeting integrins: randomized phase II trial of abituzumab in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res., 2016, 22: 3192-3200

[166] Naylor KE, et al.. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. Osteoporos. Int., 2018, 29: 1407-1417

[167] Tsourdi E, et al.. Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone, 2017, 105: 11-17

[168] Ogbureke KUE, et al.. Up-regulation of SIBLING proteins and correlation with cognate MMP expression in oral cancer. Oral. Oncol., 2007, 43: 920-932

[169] Gillespie MT, et al.. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int. J. Cancer, 1997, 73: 812-815

[170] Xu M, et al.. SB225002 inhibits prostate cancer invasion and attenuates the expression of BSP, OPN and MMP‑2. Oncol. Rep., 2018, 40: 726-736

[171] Seibel MJ, et al.. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J. Clin. Endocrinol. Metab., 1996, 81: 3289-3294

[172] Withold W, Armbruster FP, Karmatschek M, Reinauer H. Bone sialoprotein in serum of patients with malignant bone diseases. Clin. Chem., 1997, 43: 85-91

[173] Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin. Cancer Res., 2001, 7: 4060-4066

[174] Ganss B, Kim RH, Sodek J. Bone sialoprotein. Crit. Rev. Oral. Biol. Med., 1999, 10: 79-98

RIGHTS & PERMISSIONS

The Author(s)